

CITATION REPORT

List of articles citing

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction

DOI: 10.1016/j.eururo.2007.01.033
European Urology, 2007, 51, 1717-23.

Source: <https://exaly.com/paper-pdf/42947811/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
194	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>2007</i> , 3, 527-542		1
193	Editorial Comment. <i>International Journal of Urology</i> , 2007 , 14, 951-951	2.3	1
192	Lower urinary tract symptoms (LUTS) and sexual dysfunction (SD): new targets for new combination therapies?. <i>European Urology</i> , 2007 , 51, 1485-7	10.2	6
191	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , 2007 , 52, 990-1005	10.2	45
190	Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1713-25	1.1	20
189	The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. <i>International Urology and Nephrology</i> , 2008 , 40, 933-9	2.3	26
188	The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. <i>World Journal of Urology</i> , 2008 , 26, 603-9	4	76
187	Common approach to managing lower urinary tract symptoms and erectile dysfunction. <i>Asian Journal of Andrology</i> , 2008 , 10, 45-53	2.8	15
186	Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. <i>BJU International</i> , 2008 , 101, 847-52	5.6	46
185	Lower urinary tract symptoms and sexual dysfunction: a common approach. <i>BJU International</i> , 2008 , 101 Suppl 3, 22-6	5.6	26
184	Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. <i>European Urology</i> , 2008 , 53, 1228-35	10.2	111
183	Daily use of PDE5-inhibitors: the road to happiness?. <i>European Urology</i> , 2008 , 54, 28-30	10.2	2
182	Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. <i>Journal of Sexual Medicine</i> , 2008 , 5, 935-945	1.1	23
181	Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2170-8	1.1	106
180	Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. 2008 , 68, 209-29		13
179	Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. 2008 , 2008, 191-192		
178	How many drugs for LUTS due to BPH are too many?. <i>Journal of Urology</i> , 2008 , 180, 811-2	2.5	6

177	Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 111-5	2.9	15
176	Back to the Future: Introduction and Conclusions. 2008 , 7, 675-679		1
175	When to Treat the Prostate, the Bladder, or Both?. 2008 , 7, 690-695		
174	Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. <i>Journal of Urology</i> , 2008 , 180, 1042-6	2.5	17
173	Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1687-93	4	10
172	Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men. 2008 , 80, 296-9		5
171	Voiding dysfunction in men: pathophysiology and risk factors. <i>International Journal of Impotence Research</i> , 2008 , 20 Suppl 3, S2-10	2.3	4
170	Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. <i>International Journal of Impotence Research</i> , 2008 , 20, 145-9	2.3	2
169	Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. 2008 , 4, 771-82		2
168	Medical management of lower urinary tract symptoms in men: current treatment and future approaches. 2008 , 5, 211-9		14
167	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008 , 5, 355-365		2
166	New insights into the pharmacology of the bladder. 2008 , 18, 347-52		16
165	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. 2008 , 3, 511-24		43
164	Therapeutic options in the treatment of benign prostatic hyperplasia. 2009 , 3, 213-23		2
163	Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?. 2009 , 18, 245-54		1
162	PDE5 inhibitors for LUTS. 2009 , 12, 316-24		22
161	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. <i>Journal of Sexual Medicine</i> , 2009 , 6, 544-52	1.1	89
160	Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. <i>Journal of Sexual Medicine</i> , 2009 , 6, 836-47	1.1	33

159	Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. <i>International Urology and Nephrology</i> , 2009 , 41, 287-92	2.3	19
158	Benign prostatic hyperplasia evaluation, association with sexual dysfunction, treatment, and practice patterns according to physician specialty. 2009 , 7, 25-31		1
157	[Medical combination therapy in LUTS suggestive of BPH]. <i>Der Urologe</i> , 2009 , 48, 250-6		
156	[Treatment of LUTS in BPS. When and when not to administer pills?]. <i>Der Urologe</i> , 2009 , 48, 257-63		0
155	Place of overactive bladder in male lower urinary tract symptoms. <i>World Journal of Urology</i> , 2009 , 27, 723-8	4	25
154	The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. <i>Asian Journal of Andrology</i> , 2009 , 11, 716-22	2.8	8
153	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. 2010 , 64, 240-55		119
152	The effect of sildenafil citrate on bladder outlet obstruction: a mouse model. <i>BJU International</i> , 2009 , 104, 252-6	5.6	33
151	Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?. <i>BJU International</i> , 2009 , 104, 511-7	5.6	19
150	Rapid and Sensitive LCMSMS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma. 2009 , 69, 9-18		14
149	Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. <i>International Journal of Impotence Research</i> , 2009 , 21, 122-8	2.3	41
148	Vardenafil: efficacy, tolerability and future directions. 2009 , 5, 553-62		3
147	Inhibidores de la fosfodiesterasa 5 en el tratamiento de la sintomatología miccional. 2009 , 7, 156-160		
146	Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. 2009 , 19, 7-12		16
145	Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?. 2009 , 19, 49-54		15
144	Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. 2010 , 20, 49-54		38
143	The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology of voiding dysfunction and pharmacological therapy. 2010 , 112, 121-7		16
142	Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. <i>World Journal of Urology</i> , 2010 , 28, 17-22	4	70

141	Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. <i>Current Urology Reports</i> , 2010 , 11, 254-60	2.9	11
140	Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. <i>European Urology</i> , 2010 , 57, 699-707	10.2	28
139	Sexually transmitted diseases and sexual function. <i>Journal of Sexual Medicine</i> , 2010 , 7, 389-413	1.1	26
138	Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3115-26	1.1	12
137	[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article]. 2010 , 20, 616-26		2
136	Lower urinary tract symptoms. 2010 , 26, 249-60		8
135	Sexual dysfunction and the ageing male. 2010 , 65, 23-7		33
134	Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. 2010 , 21, 2-7		
133	Benign prostatic hyperplasia. 2010 , 26, 223-39		35
132	Urological aspects of the metabolic syndrome. <i>Nature Reviews Urology</i> , 2011 , 8, 483-94	5.5	69
131	Lower urinary tract symptoms and erectile dysfunction. 2011 , 22, 135-140		1
130	Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2297-313	4	12
129	Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. 2011 , 307-22		8
128	The Effect of Tamsulosin Treatment on Erectile Functions in Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostate Hyperplasia: Correlation between Improvement of LUTS and Erectile Function. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011 , 3, 15-8	1.9	2
127	Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. <i>BJU International</i> , 2011 , 107, 1104-9	5.6	34
126	Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. <i>BJU International</i> , 2011 , 107, 1943-7	5.6	32
125	JUA clinical guidelines for benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2011 , 18, e1-e33.	3.3	4
124	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. 2011 , 72, 197-204		43

123	Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). 2011 , 163, 891-907		51
122	Treatment with a uroselective α -blocker improves voiding and sexual function: a study in Thai men with lower urinary tract symptoms. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2582-9	1.1	5
121	Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. <i>European Urology</i> , 2011 , 60, 527-35	10.2	42
120	Efficacy and safety of combination therapy with mirodenafil and α -blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. <i>International Journal of Impotence Research</i> , 2011 , 23, 249-56	2.3	18
119	Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. <i>International Journal of Impotence Research</i> , 2011 , 23, 99-108	2.3	23
118	Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. 2012 , 302, E243-53		34
117	The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone. <i>International Journal of Impotence Research</i> , 2012 , 24, 221-7	2.3	5
116	The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?. <i>International Journal of Impotence Research</i> , 2012 , 24, 49-60	2.3	5
115	The recent phosphodiesterase type 5 inhibitors. <i>Human Andrology</i> , 2012 , 2, 57-64	1	
114	Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2293-306	1.1	41
113	[Medical therapy of lower urinary tract symptoms [corrected]]. <i>Der Urologe</i> , 2012 , 51, 1125-36		0
112	Re: Tadalafil Versus Solifenacin for Persistent Storage Symptoms After Prostate Surgery in Patients With Erectile Dysfunction: A Prospective Randomized Study. <i>Journal of Urology</i> , 2012 , 187, 1361-2	2.5	
111	Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. 2012 , 39, 77-88		19
110	Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α -adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. <i>Urology</i> , 2012 , 79, 875-82	1.6	20
109	Combined effect of sildenafil and guanethidine, propranolol or verapamil on erectile function in rats. 2012 , 64, 1659-66		0
108	Combination therapy in the management of LUTS [Is this the future?]. 2012 , 9, e15-e19		
107	Evaluation and Management of Urgency and Urge Urinary Incontinence in Men. <i>Current Bladder Dysfunction Reports</i> , 2012 , 7, 230-234	0.4	
106	Update on the sexual impact of treatment for benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2012 , 13, 433-40	2.9	12

105 Evaluation and Medical Management of BPH and LUTS in Men. **2012**, 55-65

104	Les inhibiteurs de la phosphodiesterase de type 5 : une révolution dans le traitement des symptômes du bas appareil urinaire?. 2012 , 22, 80-91		1
103	A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α -blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. <i>European Urology</i> , 2012 , 61, 994-1003	10.2	212
102	Monotherapy with α -blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms?. <i>European Urology</i> , 2012 , 61, 926-7	10.2	2
101	A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1624-33	1.1	53
100	Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012 , 4 Suppl 1, 75-80	1.9	2
99	Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. 2012 , 44 Suppl 1, 791-5		17
98	Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. 2013 , 27, 218-26		11
97	Effects of bipolar and monopolar transurethral resection of the prostate on urinary and erectile function: a prospective randomized comparative study. <i>BJU International</i> , 2013 , 111, 129-36	5.6	48
96	Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. <i>European Urology</i> , 2013 , 64, 228-43	10.2	67
95	Phosphodiesterase inhibitors in clinical urology. 2013 , 6, 323-32		20
94	Contemporary Combination Therapy in the Treatment of LUTS/BPH. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 134-141	0.4	
93	PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. <i>Current Bladder Dysfunction Reports</i> , 2013 , 8, 150-159	0.4	12
92	The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP. <i>Current Urology Reports</i> , 2013 , 14, 595-605	2.9	3
91	Re: Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. <i>Journal of Urology</i> , 2013 , 190, 978	2.5	
90	Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. <i>International Journal of Urology</i> , 2013 , 20, 28-39	2.3	43
89	Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. <i>Annals of Pharmacotherapy</i> , 2013 , 47, 278-83	2.9	13
88	Current pharmacological treatment options for male lower urinary tract symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1043-54	4	4

87	Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. <i>Pharmacotherapy</i> , 2013 , 33, 639-49	5.8	16
86	The role of phosphodiesterases in bladder pathophysiology. <i>Nature Reviews Urology</i> , 2013 , 10, 414-24	5.5	22
85	Use of 5-Phosphodiesterase Inhibitors in Patients with Luts Secondary to Bph: Our Experience and Review of the Literature. <i>Urologia</i> , 2013 , 80, 307-316	1.2	2
84	Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. <i>Urology Annals</i> , 2013 , 5, 237-40	1	13
83	The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. <i>BJU International</i> , 2013 , 111, 700-16	5.6	29
82	Nocturia Potentially Influences Maintenance of Sexual Function in Elderly Men with Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013 , 5, 75-81	1.9	5
81	BPH/LUTS and ED: common pharmacological pathways for a common treatment. <i>Journal of Sexual Medicine</i> , 2013 , 10, 2382-93	1.1	20
80	Efficacy and safety of the simultaneous administration of mirodenafil and an α -blocker in men with BPH-LUTS: a multicenter open-label prospective study. <i>International Journal of Impotence Research</i> , 2013 , 25, 149-54	2.3	8
79	A survey of the FAERS database concerning the adverse event profiles of α -adrenoreceptor blockers for lower urinary tract symptoms. <i>International Journal of Medical Sciences</i> , 2013 , 10, 864-9	3.7	19
78	Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms. <i>Korean Journal of Urology</i> , 2013 , 54, 100-5		5
77	The Efficacy of L-Arginine for Benign Prostatic Hyperplasia. <i>Juntendo Medical Journal</i> , 2013 , 59, 59-64	0.1	
76	Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations. <i>International Journal of General Medicine</i> , 2014 , 7, 271-6	2.3	3
75	Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014 , 6, 35-40	1.9	12
74	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. <i>Human Andrology</i> , 2014 , 4, 45-53	1	
73	The Use of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. 2014 , 113-128		
72	Combination Medical Therapy for Male Lower Urinary Tract Symptoms. 2014 , 129-153		3
71	BiVap saline vaporization of the prostate in men with benign prostatic hyperplasia: our clinical experience. <i>Urology</i> , 2014 , 83, 570-5	1.6	2
70	A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Journal of Sexual Medicine</i> , 2014 , 11, 187-96	1.1	51

69	Re: Efficacy and Safety of the Simultaneous Administration Of Mirodenafil and an α -Blocker in Men with BPH-LUTS: A Multicenter Open-Label Prospective Study. <i>Journal of Urology</i> , 2014 , 192, 1492-1494	2.5	
68	Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. <i>Drugs and Aging</i> , 2014 , 31, 425-39	4.7	10
67	The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. <i>Journal of Sexual Medicine</i> , 2014 , 11, 1539-45	1.1	34
66	The role of co-medication in the treatment of OAB. 2015 , 118-128		
65	The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. <i>Journal of Inflammation</i> , 2015 , 12, 54	6.7	23
64	Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model. <i>Neurourology and Urodynamics</i> , 2015 , 34, 286-91	2.3	13
63	Combination therapies for the management of nocturia and its comorbidities. <i>Research and Reports in Urology</i> , 2015 , 7, 57-63	1.3	9
62	Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α -adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. <i>Asian Journal of Andrology</i> , 2015 , 17, 1022-32	2.8	15
61	Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. <i>Urology</i> , 2015 , 85, 1291-9	1.6	36
60	Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. <i>Central European Journal of Urology</i> , 2016 , 69, 398-403	0.9	5
59	EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA. <i>Japanese Journal of Urology</i> , 2016 , 107, 28-33		2
58	Sexual Dysfunction in Men and Women. 2016 , 785-830		1
57	The metabolic syndrome and ED. 2016 , 109-119		1
56	Changing Discourse, Learning Sex, and Non-coital Heterosexuality. <i>Sexuality and Culture</i> , 2016 , 20, 841-861		9
55	Combination therapy for the treatment of lower urinary tract symptoms in men. <i>Revista Mexicana De Urologia</i> , 2016 , 76, 360-369	1	
54	Measurement of post-void residual urine. <i>Neurourology and Urodynamics</i> , 2016 , 35, 55-7	2.3	53
53	Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. <i>Sexual Medicine Reviews</i> , 2016 , 4, 270-284	5.6	11
52	The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. <i>BJU International</i> , 2016 , 118, 313-9	5.6	1

51	[S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia]. <i>Der Urologe</i> , 2016 , 55, 184-94		4
50	Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer. <i>World Journal of Urology</i> , 2016 , 34, 1269-74	4	11
49	Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial. <i>Arab Journal of Urology Arab Association of Urology</i> , 2017 , 15, 53-59	1.7	12
48	Emerging drugs for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 201-212	3.7	11
47	The effect of doxazosin and sildenafil citrate combination on bladder tissue contractility, alpha adrenergic receptor, and iNOS subtype expression in a male rat model of partially bladder outlet obstruction. <i>Neurourology and Urodynamics</i> , 2017 , 36, 1479-1487	2.3	3
46	Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual Function. <i>Sexual Medicine Reviews</i> , 2017 , 5, 87-102	5.6	4
45	Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2017 , 71, 570-581	10.2	36
44	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017 , 8, 99179-99202	3.3	28
43	Xybilun \square , actualit�2018�de la dysfonction �ctile. <i>Sexologies</i> , 2018 , 27, 67-71	0.5	
42	Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. <i>Aging Male</i> , 2018 , 21, 272-280	2.1	9
41	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2018 , 11, CD010060	5.2	8
40	Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. 2018 , 51-88		
39	Medical management of benign prostatic hyperplasia. 2018 , 509-525		
38	Efficacy and safety of PDE5-Is and \square blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs. <i>BMC Urology</i> , 2018 , 18, 30	2.2	5
37	Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2019 , 37, 143-153	4	9
36	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
35	Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2020 , 6, 537-558	5.1	14
34	Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. <i>World Journal of Urology</i> , 2020 , 38, 1423-1435	4	4

33	Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e22834	1.8	2
32	Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. <i>Frontiers in Immunology</i> , 2020 , 11, 451	8.4	11
31	The hemodynamic interactions of combination therapy with α -blockers and phosphodiesterase-5 inhibitors compared to monotherapy with α -blockers: a systematic review and meta-analysis. <i>International Urology and Nephrology</i> , 2020 , 52, 1407-1420	2.3	1
30	Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 1756287221993283	3.2	0
29	Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2021 , 4, e2036337	10.4	4
28	Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report. <i>Medical Science Monitor</i> , 2021 , 27, e931597	3.2	
27	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021 , 1, 82-98		
26	Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. <i>Current Clinical Urology</i> , 2014 , 121-222		1
25	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. 2012 , 2611-2654.e8		7
24	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
23	An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Asian Journal of Andrology</i> , 2011 , 13, 630-5	2.8	16
22	Combination therapy for erectile dysfunction: an update review. <i>Asian Journal of Andrology</i> , 2011 , 13, 382-90	2.8	24
21	Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e107593	3.7	33
20	Study of phosphodiesterase 5 inhibitors and α -adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 13-21	4.4	9
19	The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors. <i>Central European Journal of Urology</i> , 2014 , 67, 314-8	0.9	7
18	A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α -Blockers and α -Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction. <i>International Neurourology Journal</i> , 2015 , 19, 237-45	2.6	5
17	Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?. <i>World Journal of Nephrology</i> , 2015 , 4, 138-47	3.6	9
16	Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. <i>Korean Journal of Andrology</i> , 2011 , 29, 91		1

15	1. Pathophysiology of Voiding Dysfunction and Pharmacological Therapy. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2009 , 40, 191-199	0	0
14	The Metabolic Investigation of Erectile Dysfunction: Cardiometabolic Risk Stratification. 2015 , 145-158		
13	Erectile Dysfunction. 2015 , 65-116		
12	Physiology and Pharmacology of the Prostate. 2020 , 127-150		1
11	Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. <i>Reviews in Urology</i> , 2008 , 10, 14-25	1	61
10	Medical management of lower urinary tract symptoms. <i>Reviews in Urology</i> , 2009 , 11, S19-25	1	15
9	Metabolic syndrome and urologic diseases. <i>Reviews in Urology</i> , 2010 , 12, e157-80	1	54
8	Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. <i>Reviews in Urology</i> , 2012 , 14, 79-86	1	2
7	Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study. <i>Indian Journal of Urology</i> , 2019 , 35, 25-33	0.8	1
6	Therapeutic interventions to urologic chronic pelvic pain syndrome and UPOINT system for clinical phenotyping: How far are we?. <i>Urologia</i> , 2022 , 3915603211065301	1.2	
5	Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 763184	5.6	
4	Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022 , 94, 252-263	1.6	0
3	Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. <i>World Journal of Urology</i> , 2022 , 40, 2063-2070	4	
2	A synchronous spectrofluorometric technique for simultaneous detection of alfuzosin and tadalafil: applied to tablets and spiked biological samples. <i>Royal Society Open Science</i> , 2022 , 9,	3.3	0
1	Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients. 13,		0